Ashwin N Ananthakrishnan1, Su-Chun Cheng2, Tianxi Cai2, Andrew Cagan3, Vivian S Gainer3, Peter Szolovits4, Stanley Y Shaw5, Susanne Churchill6, Elizabeth W Karlson7, Shawn N Murphy8, Isaac Kohane9, Katherine P Liao7. 1. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: aananthakrishnan@partners.org. 2. Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. 3. Research IS and Computing, Partners HealthCare, Charlestown, Massachusetts. 4. Massachusetts Institute of Technology, Cambridge, Massachusetts. 5. Harvard Medical School, Boston, Massachusetts; Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. 6. i2b2 National Center for Biomedical Computing, Brigham and Women's Hospital, Boston, Massachusetts. 7. Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts. 8. Harvard Medical School, Boston, Massachusetts; Research IS and Computing, Partners HealthCare, Charlestown, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 9. Harvard Medical School, Boston, Massachusetts; i2b2 National Center for Biomedical Computing, Brigham and Women's Hospital, Boston, Massachusetts; Children's Hospital Boston, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Patients with inflammatory bowel diseases (IBDs) (Crohn's disease, ulcerative colitis) are at increased risk of colorectal cancer (CRC). Persistent inflammation is hypothesized to increase risk of CRC in patients with IBD; however, the few studies in this area have been restricted to cross-sectional assessments of histologic severity. No prior studies have examined association between C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) elevation and risk of CRC in an IBD cohort. METHODS: From a multi-institutional validated IBD cohort, we identified all patients with at least one measured CRP or ESR value. Patients were stratified into quartiles of severity of inflammation on the basis of their median CRP or ESR value, and subsequent diagnosis of CRC was ascertained. Logistic regression adjusting for potential confounders was used to identify the independent association between CRP or ESR elevation and risk of CRC. RESULTS: Our study included 3145 patients with at least 1 CRP value (CRP cohort) and 4008 with at least 1 ESR value (ESR cohort). Thirty-three patients in the CRP cohort and 102 patients in the ESR cohort developed CRC during a median follow-up of 5 years at a median age of 55 years. On multivariate analysis, there was a significant increase in risk of CRC across quartiles of CRP elevation (P(trend) = .017; odds ratio for quartile 4 vs quartile 1, 2.72; 95% confidence interval, 0.95-7.76). Similarly higher median ESR was also independently associated with risk of CRC across the quartiles (odds ratio, 2.06; 95% confidence interval, 1.14-3.74) (P(trend) = .007). CONCLUSIONS: An elevated CRP or ESR is associated with increased risk of CRC in patients with IBD.
BACKGROUND & AIMS:Patients with inflammatory bowel diseases (IBDs) (Crohn's disease, ulcerative colitis) are at increased risk of colorectal cancer (CRC). Persistent inflammation is hypothesized to increase risk of CRC in patients with IBD; however, the few studies in this area have been restricted to cross-sectional assessments of histologic severity. No prior studies have examined association between C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) elevation and risk of CRC in an IBD cohort. METHODS: From a multi-institutional validated IBD cohort, we identified all patients with at least one measured CRP or ESR value. Patients were stratified into quartiles of severity of inflammation on the basis of their median CRP or ESR value, and subsequent diagnosis of CRC was ascertained. Logistic regression adjusting for potential confounders was used to identify the independent association between CRP or ESR elevation and risk of CRC. RESULTS: Our study included 3145 patients with at least 1 CRP value (CRP cohort) and 4008 with at least 1 ESR value (ESR cohort). Thirty-three patients in the CRP cohort and 102 patients in the ESR cohort developed CRC during a median follow-up of 5 years at a median age of 55 years. On multivariate analysis, there was a significant increase in risk of CRC across quartiles of CRP elevation (P(trend) = .017; odds ratio for quartile 4 vs quartile 1, 2.72; 95% confidence interval, 0.95-7.76). Similarly higher median ESR was also independently associated with risk of CRC across the quartiles (odds ratio, 2.06; 95% confidence interval, 1.14-3.74) (P(trend) = .007). CONCLUSIONS: An elevated CRP or ESR is associated with increased risk of CRC in patients with IBD.
Authors: R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: Craig A Solem; Edward V Loftus; William J Tremaine; William S Harmsen; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2005-08 Impact factor: 5.325
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Siddharth Singh; James A Proudfoot; Parambir S Dulai; Vipul Jairath; Mathurin Fumery; Ronghui Xu; Brian G Feagan; William J Sandborn Journal: Am J Gastroenterol Date: 2018-06-21 Impact factor: 10.864
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao Journal: Clin Gastroenterol Hepatol Date: 2014-07-17 Impact factor: 11.382
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Katherine P Liao; Isaac Kohane Journal: Clin Gastroenterol Hepatol Date: 2016-02-22 Impact factor: 11.382
Authors: Elizabeth D Kantor; Ruzan Udumyan; Lisa B Signorello; Edward L Giovannucci; Scott Montgomery; Katja Fall Journal: Gut Date: 2015-05-18 Impact factor: 23.059
Authors: Fred K Tabung; Susan E Steck; Yunsheng Ma; Angela D Liese; Jiajia Zhang; Bette Caan; Lifang Hou; Karen C Johnson; Yasmin Mossavar-Rahmani; Nitin Shivappa; Jean Wactawski-Wende; Judith K Ockene; James R Hebert Journal: Cancer Causes Control Date: 2014-12-31 Impact factor: 2.506
Authors: Ashwin N Ananthakrishnan; Alice Cheng; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao Journal: Dig Dis Sci Date: 2014-09-12 Impact factor: 3.199